Company intelligence / Profile preview

Scalpel Ventures

Apex, North Carolina, United States

Ownership: Private
Development stage: Other

Overview

Scalpel Ventures is a healthcare-focused venture capital firm specializing in early-stage investments within the musculoskeletal, orthopedic, and broader healthcare technology sectors. Co-founded by orthopedic surgeon Dr. Selene Parekh and tech entrepreneur Saket Jain, the firm leverages deep clinical and operational expertise to back disruptive healthcare innovations, including advanced implants, regenerative medicine, and diagnostics. Scalpel Ventures utilizes a unique, flexible investment model that allows investors to select individual opportunities, providing a highly customized and transparent experience. Notable investments and exits in their portfolio include Oxford Performance Materials, Artelon, Senticell, Paragon28, Solana Surgical, and Medshape.

Therapeutic areas: RheumatologyOncology
Industry: Investors

Beyond the preview

Go deeper on Scalpel Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scalpel Ventures.

Explore the full profile